Another study suggested that EGFR amplification appears to identify a subgroup of patients with esophageal cancer who may benefit from gefitinib.34 Few studies evaluated the association between EGFR expression and survival parameters in EGFR TKIs combined with RT.35 Our study found that in the RT plus icotinib group, patients with EGFR overexpression had a significantly better OS (not reached vs 16.3 months, P = .03). The gene discussed is EGFR; the disease is esophageal cancer.